Company Overview
About Menten AI
Menten AI is a San Francisco-based AI drug discovery company — backed by Y Combinator (W20) with $4.15 million in total funding from Y Combinator, Khosla Ventures, Uncork Capital, Feld Ventures, Mana Ventures, Quain Investments, Society Health, and Volpini Ventures — developing peptide and protein therapeutics using machine learning and quantum computing to design novel cyclic peptide drug candidates for pharmaceutical licensing partnerships, completing a research collaboration with Bristol Myers Squibb in May 2024. Founded in 2018, Menten AI applies advanced AI algorithms for cyclic peptide optimization and protein structure design with a business model centered on licensing proprietary algorithms and drug candidates to pharma partners rather than developing therapeutics through full clinical development.
Business Model & Competitive Advantage
Menten AI's AI peptide design platform addresses the molecular optimization challenge in macrocyclic peptide drug discovery: cyclic peptides (peptides where the chain forms a ring structure rather than a linear sequence) have emerged as a promising drug modality that bridges small molecules (cell-permeable, bioavailable) and biologics (can engage large, flat protein-protein interaction surfaces undruggable by small molecules) — but their design is computationally difficult because the ring conformational space is exponentially larger than linear peptide space, and predicting which conformations will achieve target binding affinity and membrane permeability requires advanced computational methods. Menten AI's ML models (predicting cyclic peptide binding to target proteins, membrane permeability, metabolic stability, and pharmacokinetic properties) accelerate the design-make-test cycle for cyclic peptide drug discovery by predicting which candidates will succeed before expensive synthesis and testing.
Competitive Landscape 2025–2026
In 2025, Menten AI competes in the AI drug discovery, cyclic peptide therapeutics, and computational chemistry market with PepGen (cyclic peptide therapeutics, NASDAQ: PEPG, $300M raised), Aileron Therapeutics (stapled peptides, NASDAQ: ALRN), and Relay Therapeutics (NASDAQ: RLAY, computational drug design, $700M raised) for pharmaceutical partner AI-assisted cyclic peptide drug candidate licensing and computational design collaboration adoption. Khosla Ventures' and Uncork Capital's investments reflect deep-tech drug discovery conviction. The Bristol Myers Squibb collaboration (BMS is a top-5 global pharmaceutical company with $45B+ revenue) validates Menten AI's platform quality for industry-grade peptide design. Y Combinator W20 backing positions Menten AI within the computational biology and AI drug discovery investment community. The 2025 strategy focuses on advancing the pipeline of cyclic peptide candidates for oncology and infectious disease targets, building the quantum computing-enhanced conformational sampling for improved prediction accuracy, and expanding the pharma partnership model with additional top-20 pharmaceutical company collaborations.
Recent Activity
View all →Key Differentiators
Emerging Innovator
Menten AI is an emerging player bringing innovative solutions to the Healthcare market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
S2
S2 is an AI-powered security platform focused on vulnerability discovery and attack surface management for enterprise security teams. The company's platform combines automated scanning, AI-powered ana
athenahealth
athenahealth is a cloud-based electronic health records (EHR), medical billing, and practice management company founded in 1997 and headquartered in Watertown, Massachusetts. The company was built on
Epic Systems
Epic Systems Corporation was founded in 1979 by Judith Faulkner and is headquartered in Verona, Wisconsin, remaining privately held with Faulkner as majority owner. The company develops large-scale el
Pfizer
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The compan
Moderna
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stép
Amgen
Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of biologic
Compare Menten AI with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Menten AI? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Menten AI Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Menten AI vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →